Immunosuppressive and immunomodulatory therapies for idiopathic inflammatory myopathies

Objectives This is a protocol for a Cochrane Review (intervention). The objectives are as follows: This protocol is for two separate reviews to assess the effects (benefits and harms) of immunosuppressant and immunomodulatory treatments for the idiopathic inflammatory myopathies. Targeted treatments To assess the effects (benefits and harms) of targeted immunosuppressant and immunomodulatory treatments for the idiopathic inflammatory myopathies: dermatomyositis (DM, including juvenile dermatomyositis, jDM), immune mediated necrotising myopathy (IMNM), anti‐synthetase syndrome (ASS), overlap‐myositis (OM) and polymyositis (PM). We will also include cancer‐related myositis and amyopathic dermatomyositis. Non‐targeted treatments To assess the effects (benefits and harms) of non‐targeted immunosuppressant and immunomodulatory treatments for the idiopathic inflammatory myopathies: dermatomyositis (DM, including juvenile dermatomyositis, jDM), immune mediated necrotising myopathy (IMNM), anti‐synthetase syndrome (ASS), overlap‐myositis (OM) and polymyositis (PM). We will also include cancer‐related myositis and amyopathic dermatomyositis.